Efficacy and tolerability of milnacipran: an overview.

  title={Efficacy and tolerability of milnacipran: an overview.},
  author={Stuart A. Montgomery and Josef Prost and A Solles and Mike Briley},
  journal={International clinical psychopharmacology},
  volume={11 Suppl 4},
The relative benefits and risks of milnacipran, a novel antidepressant which selectively inhibits the reuptake of serotonin and noradrenaline, have been evaluated in comparative trials against tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs). A total of 2462 patients with major depressive disorders have been investigated. At the optimal dose (50 mg twice a day), the efficacy of milnacipran was equivalent to that of the TCAs, with response rates of… CONTINUE READING
17 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…